Sign in
Taking people in BelgiumPhase 3

Chemotherapy before chemoradiotherapy and surgery for recurrent rectal cancer

Tests chemotherapy given before chemoradiotherapy and surgery in adults with returned rectal cancer.

Key facts

Who runs it
Catharina Ziekenhuis Eindhoven
Where
Gent, BelgiumSee the siteAlso in 4 other countries, 32 sites
Registry title
Induction Chemotherapy for Locally Recurrent Rectal Cancer
Status
Recruiting
Phase
Phase 3
People taking part
364 people, planned
Started
13 Nov 2020
Expected to end
1 Mar 2030
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Combination drug
  • Chemoradiotherapy
  • Surgery locally recurrent rectal cancer
Record updated
6 September 2022

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults whose rectal cancer has come back in the same area after surgery, and where the tumour can be removed by surgery.

Age
18 years or older
Sex
All sexes can join
Disease stage
Rectal cancer that has come back locally after earlier surgery (total or partial mesorectal resection for rectal or distal sigmoid cancer). It is confirmed by tissue test or by imaging plus clinical findings. The tumour can be removed by surgery on MRI, or is judged removable after chemoradiotherapy. WHO performance score 0-1.
Earlier treatment
Must have had earlier surgery for the rectal or distal sigmoid cancer. Cannot have had any chemotherapy in the past 6 months, or radiotherapy for the first rectal cancer in the past 6 months.
Biomarker or test result
Known homozygous DPD deficiency is an exclusion. No other marker is asked for.

Main reasons for not taking part

  • Signs of cancer spread to other organs (for example liver, lung) now or in the past 6 months
  • Known homozygous DPD deficiency
  • Any chemotherapy in the past 6 months
  • Radiotherapy for the first rectal cancer in the past 6 months
  • Any reason the doctors say the planned chemotherapy, chemoradiotherapy or surgery cannot be given

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • 18 years or older
  • Confirmed locally recurrent rectal cancer after total or partial mesorectal resection for rectal or distal sigmoidal cancer either by histopathology ór clinically proven (evidence on imaging in combination with clinical findings, with consensus in MDT)
  • Resectable disease determined by magnetic resonance imaging (MRI) or deemed resectable after neoadjuvant treatment with chemoradiotherapy
  • WHO performance score 0-1
  • Written informed consent

Who cannot take part

  • Radiological evidence of metastatic disease (e.g. liver, lung) at time of randomisation or in the six months prior to randomisation
  • Any chemotherapy in the past 6 months
  • Any contraindication for the planned chemotherapy, as determined by the medical oncologist
  • Any contraindication for the planned chemoradiotherapy, as determined by the medical oncologist and/or radiation oncologist
  • Any contraindication for surgery, as determined by the surgeon and/or anaesthesiologist
  • Concurrent malignancies that interfere with the planned study treatment or the prognosis of resected LRRC
  • Radiotherapy in the past 6 months for primary rectal cancer
  • Known homozygous DPD deficiency

Where in Belgium

Also in 4 other countries, 32 sites

  • Universitair Ziekenhuis GentGent, BelgiumTaking people

About the trial

What the trial wants to find out

This is a multicentre, open-label, parallel arms, phase IIII study that randomises patients with locally recurrent rectal cancer in a 1:1 ratio to receive either induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery (experimental arm) or neoadjuvant chemoradiotherapy and surgery alone (control arm)

The 2 groups in the trial

  • Induction chemotherapy + chemoradiotherapy + surgeryTreatment being tested

    Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery

    Treatment: Combination drug, Chemoradiotherapy, and Surgery locally recurrent rectal cancer

  • Neoadjuvant chemotherapy + surgeryExisting treatment, for comparison

    Neoadjuvant chemoradiotherapy followed by surgery

    Treatment: Chemoradiotherapy and Surgery locally recurrent rectal cancer

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
Multicentre, Open-label, Randomised, Controlled, Parallel Arms Clinical Trial of Induction Chemotherapy Followed by Chemoradiotherapy Versus Chemoradiotherapy Alone as Neoadjuvant Treatment for Locally Recurrent Rectal Cancer - PelvEx II
Plain-language title
Chemotherapy before chemoradiotherapy and surgery for recurrent rectal cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
6 September 2022